Cover Image
市場調查報告書

抗菌藥:全球產業及市場預測

Antibacterial Drugs: World Industry and Market Prospects 2016-2026

出版商 Visiongain Ltd 商品編碼 226947
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗菌藥:全球產業及市場預測 Antibacterial Drugs: World Industry and Market Prospects 2016-2026
出版日期: 2016年03月29日 內容資訊: 英文 300 Pages
簡介

全球抗菌藥市場由於主要企業的潛力而可望成長,預測到2020年將達到441億3,000萬美金。

本報告提供全球抗菌藥的市場相關調查,提供您感染疾病及抗菌藥概要,主要藥物類別的市場趨勢,成長推進因素·阻礙要素,收益規模的變化與預測,市場佔有率的變化預測,主要經營者及領導品牌趨勢,並彙整地區及主要國家的趨勢,開發平台狀況,專家的採訪,今後的產業預測等資料。

第1章 報告概要

第2章 關於簡介:抗菌藥

  • 細菌感染的種類
  • 引起感染疾病的主要細菌
  • 一般細菌感染的發病率和死亡率
  • 感染疾病的治療
    • 抗菌藥的發展歷史
    • 作用機制
    • 主要藥物類別
    • 抗生素抗藥性

第3章 全球抗菌藥市場展望

  • 持續持平趨勢的抗菌藥收益
  • 抗菌劑:市場區隔
  • 抗菌藥市場預測:Fluoroquinolones 的收益減少
  • 成長推進因素·阻礙要素
  • 學名藥的衰退和處方箋管理市場成長制動器
  • Pfizer:抗菌藥市場領導
  • 分散市場新的片斷化

第4章 頭孢菌素市場預測

  • 頭孢菌素市場現狀:的缺乏支配性品牌
    • 後期階段的頭孢菌素今後市場佔有率擴大
    • Basilea·Merck·Actavis·AstraZeneca成為今後的主導企業
    • 成長推進因素·阻礙要素
    • 沒有市場優先權的頭孢菌素
    • 新頭孢菌素的強力開發平台
    • Rocephin (Roche):美國淋病的唯一治療方法
    • Sulperazon:印度的呼吸系統感染疾病(RTI)·泌尿道感染(UTI)的有代表性治療方法
    • Zinnat/Ceftin:GSK的既成頭孢菌素
    • Meiact:各種針對社區性感染症的抗菌藥
    • Flomox:鹽野義製藥的第三代頭孢菌素
    • Zinforo/Teflaro (Ceftaroline Fosamil):第一次的第五代頭孢菌素
    • Zeftera (Ceftobiprole):通過歐洲肺炎治療藥認證
    • CXA-201 (Ceftrolozane-Tazobactam):下一個重量級抗菌藥
    • CAZ-AVI (Ceftazidime-Avibactam):得到核准

第5章 青霉素市場預測

  • 學名藥和Augmentin壟斷市場
  • 青霉素的市場佔有率:Augmentin今後10年將喪失獨佔地位
  • 青霉素的市場規模預測
  • 成長推進因素·阻礙要素
  • Augmentin:面臨與學名藥競爭的暢銷藥物
  • Zosyn/Tazocin (Piperacillin-Tazobactam):肺炎的治療藥
  • Unasyn:革蘭氏陰性菌/陽性菌抗菌藥
  • Amoxil (Amoxicillin):歷史性的抗菌藥品牌
  • Amoxicillin的學名藥
  • Clavulanic Acid:Amoxicillin的學名藥

第6章 Fluoroquinolones 市場預測

  • Fluoroquinolones 市場現狀
  • 市場佔有率的變動預測
  • Fluoroquinolone抗菌藥市場預測
  • Fluoroquinolones 市場趨勢
  • 市場預測
  • Avelox
  • Cravit·Levaquin
  • Vigamox
  • Cirpodex及Cipro:Ciprofloxacin的二種籌備藥
  • Geninax
  • Delafloxacin

第7章 大環內酯類市場預測

  • 大環內酯類市場現狀
  • 市場佔有率的變動預測
  • 市場預測
  • 市場趨勢
  • Biaxin/Clarith
  • Zithromax
  • Dalacin
  • Dificid
  • Solithromycin

第8章 碳青霉烯類市場預測

  • 碳青霉烯類市場現狀
  • 市場佔有率的變動預測
  • 市場預測
  • 市場趨勢
  • Merrem/Meropenem
  • Primaxin
  • Invanz
  • Doribax

第9章 其他抗菌藥的預測

  • 其他的藥物類別的市場
  • 市場佔有率的變動
  • 市場預測
  • 市場趨勢
  • Zyvox:有代表性的抗菌藥
  • Cubicin:ABSSSI的代表性品牌
  • Tygacil:通過多適應症認證的四環黴素
  • TOBI/TOBI Podhaler:囊腫纖維化的代表性吸入器
  • Solodyn:嚴重痤瘡的治療藥
  • Vibativ:新Lipoglycopeptide的特定未來性
  • Sirturo:針對多重抗藥性TB(結核)的新選擇
  • Tedizolid:是否能成為繼Zyvox之代表性醫藥品?
  • Oritavancin:附新PK簡介的抗菌藥
  • Dalbavancin:適應症市場上的激烈競爭
  • Surotomycin:梭狀桿菌(C. difficile)治療藥
  • Nemonoxacin:台灣的全球市場抗菌藥

第10章 主要國家市場預測

  • 美國·中國壟斷市場,但原因各不相同
  • 美國市場:市場成長預測將是整體平均以上
  • 預測中國的市場佔有率停頓和巴西·印度的市場佔有率擴大
  • 全球各國感染疾病的發病情形
  • 全球各國的抗菌藥使用概況
  • 美國的抗菌藥市場
  • EU(歐洲聯盟):全球第二大市場
  • 日本:依然佔全球第4位
  • 韓國:抗菌藥的利用水準今後是否仍然偏高?
  • 金磚四國:市場預測更進一步擴大
  • 中國:由於過度使用抗菌藥而擴大市場
  • 印度:今後10年預測將擴大50%
  • 巴西:預測將增加2倍
  • 俄羅斯:由於TB流行的市場成長預測

第11章 抗菌藥研發產品線的評估

  • 克陽性vs.革蘭氏陰性
  • 小分子藥獨佔的開發平台
  • 第三階段的候補藥
  • 第二階段的主要抗菌劑候補藥
  • 吸入抗菌藥
  • 生物製藥:最新的治療藥
  • 其他級

第12章 抗菌藥的市場及產業的定性分析

  • SWOT分析
  • STEP分析
  • 市場的成熟化與強力的需求預測
  • 全球各國感染疾病的高盛行率
  • 全球的抗菌藥需求
  • 感染疾病的動物模式:與其它治療領域相比未來性遙遙領先
  • 飽和化市場的進入
  • 對學名藥的優勢等

第13章 專家的調查採訪

第14章 結論

  • 目前三大暢銷藥物(代表性品牌)
  • 未來代表性的品牌抗菌藥
  • 抗菌藥開發平台趨勢預測
  • 阻止抗菌藥的抗性
  • 抗菌藥臨床開發的變化

附錄

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0101

Antibacterial Drugs: World Industry and Market Prospects 2016-2026 - our new study reveals trends, R&D progress, and predicted revenues

Where is the Antibacterial Drugs market heading? Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 300 page report provides 124 tables and 97 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibacterial Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
  • Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
    • Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
  • Discusses the dynamic of the antibacterial drugs market and the company's drug candidate, AIC499 for the treatment of Gram-negative infections.
    • Dr Bruce R. Donald (Duke University) Dr Amy C. Anderson (University of Connecticut), Mr. Pablo Gainza-Cirauqui (Duke University)
  • Discusses OSPREY, the protein-design algorithm to predict mutation.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:

  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Other antibiotics.

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those antibacterial drugs?

How will individual antibacterial drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these brands:

  • Cephalosporins
    • Rocephin
    • Sulperazon
    • Ceftin/Zinnat
    • Meiact
    • Flomox
    • Teflaro
    • Zeftera
    • Ceftolozane-tazobactam
    • Ceftazidime-Avibactam
  • Penicillins
    • Generic amoxicillin
    • Augmentin
    • Zosyn/Tazocin
    • Unasyn
    • Generic amoxicllin-clavulanic acid
    • Amoxil
  • Fluoroquinolones
    • Avelox
    • Cravit
    • Vigamox
    • Ciprodex
    • Cipro/Cirpobay
    • Geninax
    • Defafloxacin
  • Macrolides
    • Biaxin/Clarith
    • Zithromax
    • Dalacin
    • Dificid
    • Solithromycin
  • Carbapenems
    • Invanz
    • Merrem/Meropen
    • Primaxin
    • Doribax
  • Other antibiotics
    • Zyvox
    • Cubicin
    • Tygacil
    • TOBI/TIP
    • Solodyn
    • Vibativ
    • Sirturo
    • Tedizolid
    • Oritavancin
    • Dalbavancin
    • Nemonoxacin
    • Surotomycin

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).
  • South Korea

This chapter also provides incidence of infection and antibacterial drug consumption by country.

Leading companies and the potential for market growth

Our analyses forecasts the world market for antibacterial drug market will reach $44.13bn in 2020.

You can also see which companies hold the most potential:

  • Pfizer
  • Merck & Co.
  • GlaxoSmithKline
  • Novartis
  • Bayer
  • Taisho Pharmaceuticals
  • AstraZeneca
  • Abbott Labs
  • Daiichi Sankyo

Research and development - assess innovation, trends and possibilities

Our report discusses R&D, appraising technological, clinical and commercial possibilities. There are 19 antibacterial drugs in phase III trials. Our report discusses:

  • Small Molecule Antibacterial Drugs
  • Inhaled Antibacterial Drug Formulations
  • Biological Antibacterial Therapeutics
  • Other Classes

How the Antibacterial Drug Market report helps you

  • Revenues for antibacterial drug market to 2026 - assess the overall world drugs market's potential and receive forecasted revenues.
  • Products' sales to 2026 - discover the predicted revenues of Zyvox, Cubicin,and Augmentin, amongst other leading brands.
  • National market forecasting to 2026 for 12 countries - explore the best regions for treatment demand, sales and growth
  • R&D activities - see the progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities
  • Leading companies - examine the participants, including Pfizer, Merck & Co., and GlaxoSmithKline.
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantage.
  • Two interviews with stakeholders in the antibacterial drug market.

Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.

Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2026 for the antibacterial drug market.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analysis
  • 1.5. Who is This Study For?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports

2. Introduction to Antibacterial Drugs

  • 2.1. Types of Bacterial Infection
  • 2.2. Main Bacteria Causing Infections in Human Beings
  • 2.3. Incidence and Mortality Profiles for Common Bacterial Infection
  • 2.4. Treating Infections
    • 2.4.1. The History of Antibacterial Drug Development
    • 2.4.2. Mechanisms of Action
    • 2.4.3. Leading Classes of Antibacterial Medicines
      • 2.4.3.1. Cephalosporins
      • 2.4.3.2. Penicillins
      • 2.4.3.3. Carbapenems
      • 2.4.3.4. Fluoroquinolones
      • 2.4.3.5. Macrolides
    • 2.4.4. Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market, 2016-2026

  • 3.1. Antibacterials' Revenues Plateau between 2010 and 2015
  • 3.2. Antibacterial Agents - Market Segmentation
  • 3.3. Antibiotics Market Forecast, 2016-2026: Decline in Revenues for Fluoroquinolones
  • 3.4. Drivers and Restraints in the Antibacterials Market, 2016-2026
  • 3.5. Generic Erosion and Prescription Control will Limit Market Growth
  • 3.6. Changes in that Industry Sector's Market Shares, 2016-2026
  • 3.7. Pfizer is the Leader in the Antibacterial Drugs Market, 2014
  • 3.8. Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast, 2016-2026

  • 4.1. Cephalosporins Market 2015 - No Dominant Brands
    • 4.1.1. Late-Stage Cephalosporins to Gain Market Share Between 2016 and 2026
    • 4.1.2. Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2016 and 2026
    • 4.1.3. Drivers and Restraints on the Cephalosporins Market, 2016-2026
    • 4.1.4. Cephalosporins Lack Market Exclusivity
    • 4.1.5. Strong Pipeline for Novel Cephalosporins
    • 4.1.6. Rocephin (Roche) - The Only Treatment for Gonorrhoea in the US
      • 4.1.6.1. Off Patent but Still Effective
      • 4.1.6.2. Declining Revenues Owing to Competition - Forecast 2016-2026
    • 4.1.7. Sulperazon - India's Leading Treatment for RTIs and UTIs
      • 4.1.7.1. Continued Growth in the Emerging Markets, Revenue Forecast 2016-2026
    • 4.1.8. Zinnat/Ceftin - GSK's Established Cephalosporin
      • 4.1.8.1. Continued Decline in Revenue - Forecast 2016-2026
    • 4.1.9. Meiact - A Broad Range Community Antibiotic
      • 4.1.9.1. Spectracef Sales in the US Leads to Pass the Product
      • 4.1.9.2. Competition in Japan to Hinder Growth - Revenue Forecast 2016-2026
    • 4.1.10. Flomox - Shionogi's Third-Generation Cephalosporin
      • 4.1.10.1. Patent Issues and Litigation
      • 4.1.10.2. Genericisation and Safety to Restrict Sales - Forecast 2016-2026
    • 4.1.11. Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
      • 4.1.11.1. Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2016-2026
    • 4.1.12. Zeftera (ceftobiprole): Approved for Pneumonia in Europe
      • 4.1.12.1. Future Sales Dictated by US Approval - Revenue Forecast 2016-2026
    • 4.1.13. CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
      • 4.1.13.1. Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast 2016-2026
    • 4.1.14. CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
      • 4.1.14.1. Competition from CXA-201 to Limit Sales - Forecast 2016-2026

5. Penicillins Market Forecast, 2016-2026

  • 5.1. Generics and Augmentin Dominate the Penicillins Market in 2015
  • 5.2. Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin Drugs, 2016-2026
  • 5.3. Penicillin Antibacterials: Market Forecast 2016-2026
  • 5.4. Drivers and Restraints for the Penicillin Market 2016-2026
  • 5.5. Augmentin - Blockbuster Facing Generic Competition
    • 5.5.1. Augmentin - Challenges in Some Countries
    • 5.5.2. Stable Revenues in Spite of Generic Competition
    • 5.5.3. Revenue Forecast 2016-2026
  • 5.6. Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
    • 5.6.1. Patent Expiry and Revenue Extension for Pfizer
    • 5.6.2. Historic and Current Revenue Performance
    • 5.6.3. Revenue Forecast 2016-2026
  • 5.7. Unasyn - Gram-negative and Positive Antibiotic
    • 5.7.1. Falling Revenues - Forecast 2016-2026
  • 5.8. Amoxil (Amoxicillin) - A Historic Antibacterial Brand
    • 5.8.1. Marginal Decline in Revenue - Forecast 2016-2026
  • 5.9. Generic Amoxicillin
    • 5.9.1. Revenue Forecast 2016-2026
  • 5.10. Generic Amoxicillin-Clavulanic Acid
    • 5.10.1. Revenue Forecast 2016-2026

6. Fluoroquinolone Market Forecast, 2016-2026

  • 6.1. The Fluoroquinolone Market 2015
  • 6.2. Changing Market Share for Fluoroquinolone Antibacterials, 2016-2026
  • 6.3. Fluoroquinolone Antibacterial Drugs: Market Forecast 2016-2026
  • 6.4. Trends in the Fluoroquinolone Market
    • 6.4.1. Safety Fears for Fluoroquinolones
    • 6.4.2. Avelox Patent Cliff
    • 6.4.3. Inhaled Fluoroquinolone Formulations
  • 6.5. Fluoroquinolone Market Forecast 2016-2026
  • 6.6. Avelox
    • 6.6.1. Safety Profile Hampers Sales
    • 6.6.2. Generic Competition
    • 6.6.3. Revenue Forecast 2016-2026
  • 6.7. Cravit and Levaquin
    • 6.7.1. Generic Competition Affecting Revenue Worldwide
    • 6.7.2. Lifecycle Management for Cravit and Levaquin
    • 6.7.3. Revenue Forecast 2016-2026
  • 6.8. Vigamox
    • 6.8.1. Branded and Generic Challenges 2010-2013
    • 6.8.2. Moxeza: A Next-Generation Form of Vigamox
    • 6.8.3. Revenue Forecast 2016-2026
  • 6.9. Cirpodex and Cipro - Two Preparations of Ciprofloxacin
    • 6.9.1. Ciprodex: A Second-Generation Ophthalmic Antibiotic
      • 6.9.1.1. Revenue Forecast 2016-2026
    • 6.9.2. Cipro Revenue Forecast 2016-2026: Continued Generic Erosion
  • 6.10. Geninax
    • 6.10.1. Revenue Forecast 2016-2026
  • 6.11. Delafloxacin
    • 6.11.1. Revenue Forecast 2016-2026

7. Macrolide Market Forecast, 2016-2026

  • 7.1. Macrolide Market in 2015
  • 7.2. Changing Market Share for Macrolides, 2016-2026
  • 7.3. Macrolide Antibacterials: Market Forecast 2016-2026
  • 7.4. Trends in the Macrolide Market
  • 7.5. Biaxin/Clarith
    • 7.5.1. Past Revenue 2011-2014
    • 7.5.2. Lifecycle Management for Continued Market Presence
    • 7.5.3. Revenue Forecast 2016-2026
  • 7.6. Zithromax
    • 7.6.1. Concerns Over Safety and Marketing in the US
    • 7.6.2. Effectiveness in Drug-Resistant Strains
    • 7.6.3. Revenue Forecast 2016-2026
  • 7.7. Dalacin
    • 7.7.1. Revenue Forecast 2016-2026
  • 7.8. Dificid
    • 7.8.1. Rapid Uptake Slowed by High Cost
    • 7.8.2. New Approvals and Expanded Indications
    • 7.8.3. Revenue Forecast 2016-2026
  • 7.9. Solithromycin
    • 7.9.1. Revenue Forecast 2016-2026

8. Carbapenem Market Forecast, 2016-2026

  • 8.1. Carbapenem Market 2015
  • 8.2. Changing Market Share for Carbapenems, 2016-2026
  • 8.3. Carbapenem Market Forecast, 2016-2026
  • 8.4. Trends in the Carbapenem Market
    • 8.4.1. Rising Prevalence of Carbapenemases and β-Lactamases
    • 8.4.2. No New Carbapenems in Late-Stage Trials
  • 8.5. Merrem/Meropenem
    • 8.5.1. Generics Affecting Revenue Worldwide
    • 8.5.2. Revenue Forecast 2016-2026
  • 8.6. Primaxin
    • 8.6.1. Combination Therapy for Lifecycle Management
    • 8.6.2. Historic and Current Revenues
    • 8.6.3. Revenue Forecast 2016-2026
  • 8.7. Invanz
    • 8.7.1. Revenue Forecast 2016-2026
  • 8.8. Doribax
    • 8.8.1. Doribax in HAP and VAP
    • 8.8.2. Lifecycle Management in Japan and the Rest of the World
    • 8.8.3. Revenue Forecast 2016-2026

9. Other Antibiotic Drugs Forecast, 2016-2026

  • 9.1. The Market for Other Classes of Antibacterial Drugs
  • 9.2. Changing Market Share for Fluoroquinolone Antibacterials 2016-2026
  • 9.3. Other Antibacterials: Market Forecast, 2016-2026
  • 9.4. Trends in the Other Classes of Antibacterial Drugs
    • 9.4.1. New Oxazolidinones Will Drive Growth
    • 9.4.2. New Drug Classes to Drive Submarket Growth to 2026
  • 9.5. Zyvox - The Market Leading Antibacterial
    • 9.5.1. MRSA Activity Driving Revenue Growth
    • 9.5.2. Promise in Tuberculosis and Anthrax
    • 9.5.3. Patents, Litigation, and Competition - When and Who Will Produce Generic Linezolid?
    • 9.5.4. Flat Growth to Patent Expiry, Revenue Forecast 2016-2026
  • 9.6. Cubicin - The Leading Brand for ABSSSIs
    • 9.6.1. Revenue Boosted by Approvals Worldwide
    • 9.6.2. Patents, Litigation and Deals - How Long Will Market Exclusivity Last?
    • 9.6.3. Sustained Growth through to 2020, Revenue Forecast 2016-2026
  • 9.7. Tygacil - A Tetracycline With Many Approved Indications
    • 9.7.1. Concerns Limiting Revenue Potential
    • 9.7.2. Competition from Other Therapies Restricts Growth: Revenue Forecast 2016-2026
  • 9.8. TOBI/TOBI Podhaler - The Market Leading Inhaler for Cystic Fibrosis
    • 9.8.1. Historic and Current Revenue Performance
    • 9.8.2. Approvals and Launches in New Markets to Drive Revenue Growth
    • 9.8.3. Competition to Limit Long-term Growth, Revenue Forecast 2016-2026
  • 9.9. Solodyn - A Treatment for Severe Acne
    • 9.9.1. Generic Competition and Lifecycle Management
    • 9.9.2. Limited Potential for Dermatology, Revenue Forecast 2016-2026
  • 9.10. Vibativ - Limited Potential for Novel Lipoglycopeptide
    • 9.10.1. Astellas Ends its Collaboration with Theravance
    • 9.10.2. Limited HAP Label in the US - Revenue Forecast 2016-2026
  • 9.11. Sirturo - A New Option for Multi-Drug Resistant TB
    • 9.11.1. Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2016-2026
  • 9.12. Tedizolid - Market Leading Follow-on to Zyvox?
    • 9.12.1. Competition Increasing: Revenue Forecast 2016-2026
  • 9.13. Oritavancin - An Antibiotic With a Novel PK Profile
    • 9.13.1. Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2016-2026
  • 9.14. Dalbavancin - Competing in a Crowded Indication
    • 9.14.1. Sustained Growth Over the Coming 10 Years, Revenue Forecast 2016-2026
  • 9.15. Surotomycin -Treatment for C. difficile
    • 9.15.1. Delayed Launch to Limit Potential, Revenue Forecast 2016-2026
  • 9.16. Nemonoxacin - Taiwan's Global Antibacterial Drug
    • 9.16.1. Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2016-2026

10. The Leading National Markets, 2016-2026

  • 10.1. US and China Dominate the Global Antibacterial Market, But For Different Reasons
  • 10.2. Above-Average Growth in US: Regional Forecasts, 2016-2026
  • 10.3. China to Slump in Market Share, While Brazil and India Push on
  • 10.4. Incidence of Infection by Country, 2015
    • 10.4.1. Incidence of Pneumonia in National Markets - Pneumonia Predominant in America
    • 10.4.2. Incidence of Community Acquired Urinary Tract Infections in National Markets - High Incidence Rates in the UK, US and Spain
    • 10.4.3. Incidence of Bacterial Skin and Skin Structure Infections in National Markets - High Potential in the US
    • 10.4.4. Incidence of Upper Respiratory Tract Infections in National Markets - Europe Leads the Way
  • 10.5. Antibacterial Drug Consumption by Country, 2015
    • 10.5.1. Antibacterial Drug Consumption in the Major National Markets
    • 10.5.2. Antibacterial Drug Consumption in Some Other National Markets
  • 10.6. The Antibacterials Market in the US
    • 10.6.1. Continued Dominance of the US Market
  • 10.7. The European Union Forms Second Largest Regional Market
    • 10.7.1. Marginal Expansion in Antibacterial Spending - Market Forecast 2016-2026
    • 10.7.2. Action to Encourage Antibacterial Drug Development in the EU
    • 10.7.3. Italy Continues to Lead the Way in Antibiotic Use
    • 10.7.4. The French Fascination with Expensive Antibacterial Drugs
    • 10.7.5. Germany - Europe's Antibiotic Steward
    • 10.7.6. Rising Use of Antibacterials Drugs in the UK
    • 10.7.7. Spanish Antibacterials Market to Expand from 2020 to 2026
  • 10.8. Japan - Still the Fourth Largest National Market
    • 10.8.1. The Pause Before Growth in the Japanese Market
  • 10.9. Will South Korea Continue Its High Use of Antibiotics?
  • 10.10. BRIC Nation Sales Still Expanding - Market Forecast 2016-2026
  • 10.11. Chinese Antibacterial Market Bloated by Reported Overuse
    • 10.11.1. Developing Antibacterials in China, for China
    • 10.11.2. Governmental Controls Subdue Recent Growth - Market Forecast 2016-2026
  • 10.12. Indian Market to Expand by 50% Over the Forecast Period
    • 10.12.1. Restricting Antibiotic Use in India
    • 10.12.2. Sustained Expansion of the Indian Market, Forecast 2016-2026
  • 10.13. Brazilian Antibacterial Market to Double in Size
    • 10.13.1. Brazilian Market to Be Driven by Drug Resistance
  • 10.14. Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2016-2026

11. Antibacterials R&D Pipeline Review, 2016

  • 11.1. Gram-Positive vs. Gram-Negative
  • 11.2. Pipeline Dominated by Small Molecule Drugs
  • 11.3. Leading Phase III Pipeline Treatment Candidates
    • 11.3.1. Surotomycin - Broad C. difficile Treatment to Reduce Relapse
    • 11.3.2. Tedizolid - More Potent Than Zyvox with Fewer Doses?
    • 11.3.3. Delafloxacin - A Leading pH Activated, Broad Spectrum Fluoroquinolone
    • 11.3.4. Solithromycin - Fluroketolide with Favourable Side Effect Profile
    • 11.3.5. Eravacycline - Treating Gram-Negative cUTIs and cIAIs
    • 11.3.6. Plazomicin - Straight to PIII in Carbapenem Resistant Infections
    • 11.3.7. Cadazolid: Largest PIII C. Difficile Trial
    • 11.3.8. Omadacycline - Another Phase III-Ready Partnership
    • 11.3.9. Relebactam - A Novel β-Lactamase Combination
    • 11.3.10. CEM-102 (Fusidic acid) - Cempra's Second Pipeline Candidate
    • 11.3.11. BC-3781- Unique Mechanism of Action at 23S?
  • 11.4. Leading Phase II Antibacterial Drug Candidates
    • 11.4.1. AZD5847: An Oxazolidinone for TB
    • 11.4.2. Radezolid - Apparently on Melinta's Back-Burner for Now
    • 11.4.3. AFN-1252: Highly Specific S. Aureus Antibacterial
    • 11.4.4. TD-1792 - A Russian Antibacterial Medicine
    • 11.4.5. Brilacidin - A Novel Peptide Antibacterial Agent
    • 11.4.6. POL7080 - Polyphor and Roche in Multi-Million Dollar Deal
  • 11.5. Inhaled Antibiotics - Advantages in Lung Infections
    • 11.5.1. Cayston: Competition for Novartis?
    • 11.5.2. ARIKACE - Targeting P. aeruginosa
    • 11.5.3. Aeroquin - Better than Podhaler?
    • 11.5.4. BAYQ3939 - Developments for Cystic Fibrosis
    • 11.5.5. NKTR-061: Targeting Intubated Pneumonia
    • 11.5.6. Pulmaquin: A Second Ciprofloxacin Candidate
    • 11.5.7. AeroVanc Targets MRSA Infections
    • 11.5.8. Inhaled Amikacin-Fosfomycin - Adjunctive Therapy for VAP
  • 11.6. Biologics - Truly Novel Antibacterial Therapeutics
    • 11.6.1. MK-3415A: First Antibacterial mAb to the Market?
    • 11.6.2. KB001A - The Leading Antibody Against P. aeruginosa
    • 11.6.3. Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
    • 11.6.4. MEDI4893 - Early Stage mAb to S. Aureus
  • 11.7. Other Classes
    • 11.7.1. AZD0914 - Novel DNA Gyrase Inhibitor
    • 11.7.2. MRX-I - Safer Oral Oxazolidinone to Treat MRSA
    • 11.7.3. GSK2140944 - BTI Class of Antibiotics
    • 11.7.4. Carbavance - to Treat CRE

12. Qualitative Analysis of the Antibacterials Industry and Market, 2016

  • 12.1. SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
  • 12.2. STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
    • 12.2.1. Social Factors
    • 12.2.2. Technological Developments
    • 12.2.3. Economic Pressures
    • 12.2.4. Political Issues
  • 12.3. Market is Well Established and Demand Will Remain Strong
  • 12.4. High Prevalence of Bacterial Infection Worldwide
  • 12.5. Worldwide Demand for Antibacterials
  • 12.6. Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
  • 12.7. Cutting into a Saturated Market
  • 12.8. Superior Benefit over Generics?
  • 12.9. Resistance - Nature's Patent Expiry
  • 12.10. Acute Treatment Limits Commercial Potential
  • 12.11. Did Big Pharma Back Away from Antibacterial Drugs?
  • 12.12. Resistance Will Continue to Present New Targets
  • 12.13. First Biologic Antibacterials
  • 12.14. Potential for Smaller Firms to Capitalise
  • 12.15. Developing Preventative Vaccines Rather Than Treatments
  • 12.16. Antibacterial Stewardship Reduces Usage
  • 12.17. Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
    • 12.17.1. Therapeutic Success in European Clinical Trials
    • 12.17.2. Primary End Points in FDA Guidelines
  • 12.18. Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
  • 12.19. Enticing Antibacterial Drug Discovery - Push and Pull Incentives
    • 12.19.1. GAIN act: Post-Development Pull Incentives in the US
    • 12.19.2. ADAPT - Building on the GAIN act
    • 12.19.3. EMA Update Guideline - Streamlining Clinical Trials in the EU
    • 12.19.4. Push Incentives for Antibacterial Drug Discovery with Public Funding
    • 12.19.5. IMI: Public-Private Collaboration with GSK and AstraZeneca
    • 12.19.6. Public Finance Pumping Money into Antibacterial Development

13. Research Interviews from Our Survey

  • 13.1. Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
    • 13.1.1. AiCuris Anti-infective Cures GmbH
    • 13.1.2. Introduction
    • 13.1.3. Antibacterial Drugs Market - What Dynamic Have You Observed?
    • 13.1.4. Antibacterial Drugs Market - Drivers and Restraints
    • 13.1.5. What Technological Advances Will Benefit the Antibacterial Drugs Market?
    • 13.1.6. The Burden of Carbapenem-resistant organisms in Germany
    • 13.1.7. AiCuris - Present Development Status of AIC499
  • 13.2. Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut), and Mr. Pablo Gainza-Cirauqui (Duke University)
    • 13.2.1. OSPREY
    • 13.2.2. OSPREY - Specializes in Accurate Negative Design
    • 13.2.3. Technical Challenges in Predicting Mutations
    • 13.2.4. Success Rate - Top Four Predictions Confirmed in vitro
    • 13.2.5. OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
    • 13.2.6. Further Work: Optimize Antibody for Highest in vivo Efficacy
    • 13.2.7. Anticipate Mutations - Redesign Drugs to Maximize Effective Lifespan

14. Antibacterial Drugs Market to 2026: Conclusions

  • 14.1. Three Blockbuster Antibacterials in 2015, Leading Brands
  • 14.2. The Leading Branded Antibacterial Drugs in 2026
  • 14.3. Signs of Life in the Antibacterial R&D Pipeline
  • 14.4. Stemming the Tide of Antibacterial Drug Resistance
  • 14.5. The Changing Face of Antibacterial Clinical Development

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
  • Table 2.1: Common Bacterial Infections and Their Causes
  • Table 2.2: Details of the ESKAPE Bacteria
  • Table 2.3: Leading Causes of Infectious Diseases Deaths Worldwide, 2010
  • Table 2.4: Mechanisms of Action for Antibacterial Drugs, 2015
  • Table 3.1: Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2010-2015
  • Table 3.2: Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2015
  • Table 3.3: Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
  • Table 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2015-2026
  • Table 3.5: Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2014
  • Table 4.1: Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
  • Table 4.2: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2015
  • Table 4.3: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2020
  • Table 4.4: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2026
  • Table 4.5: Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.6: Cephalosporin Market Forecast by Product: Market Share (%), 2015-2026
  • Table 4.7: Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.8: Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.9: Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.10: Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.11: Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.12: Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
  • Table 4.13: Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.14: Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.15: Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 4.16: Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.1: Leading Branded Penicillin Drugs: Important Facts
  • Table 5.2: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2015
  • Table 5.3: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2020
  • Table 5.4: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2026
  • Table 5.5: Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.6: Penicillin Market Forecast by Product: Market Share (%), 2015-2026
  • Table 5.7: Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.8: Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.9: Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.10: Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.11: Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 5.12: Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.1: Leading Branded Fluoroquinolone Drugs: Important Facts
  • Table 6.2: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2015
  • Table 6.3: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2020
  • Table 6.4: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2026
  • Table 6.5: Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.6: Fluoroquinolone Market Forecast by Product: Market Share (%), 2015-2026
  • Table 6.7: Global Patent Expiration Dates for Avelox
  • Table 6.8: Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.9: Generic Manufacturers of Levofloxacin, 2015
  • Table 6.10: Cravit and Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.11: Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.12: Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.13: Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.14: Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 6.15: Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.1: Leading Branded Macrolides: Important Facts
  • Table 7.2: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2015
  • Table 7.3: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2020
  • Table 7.4: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2026
  • Table 7.5: Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.6: Macrolide Market Forecast by Product: Market Shares (%), 2015-2026
  • Table 7.7: Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.8: Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.9: Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.10: Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 7.11: Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 8.1: Leading Branded Carbapenems: Important Facts
  • Table 8.2: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2015
  • Table 8.3: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2020
  • Table 8.4: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2026
  • Table 8.5: Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 8.6: Carbapenem Market Forecast by Product: Market Share (%), 2015-2026
  • Table 8.7: Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 8.8: Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 8.9: Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 8.10: Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.1: Other Leading Branded Antibacterials: Important Facts
  • Table 9.2: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2015
  • Table 9.3: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2020
  • Table 9.4: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2026
  • Table 9.5: Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.6: Other Agents: Market Forecast by Product - Market Share (%), 2015-2026
  • Table 9.7: Oxazolidinones in Mid to Late Stage Clinical Development, 2015
  • Table 9.8: Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.9: Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.10: Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.11: TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.12: Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.13: Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.14: Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.15: Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.16: Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.17: Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.18: Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 9.19: Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.1: Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2015
  • Table 10.2: Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2015-2026
  • Table 10.3: Antibacterial Drug Markets: National and Regional Market Shares (%), 2015-2026
  • Table 10.4: Incidence of Pneumonia in National Markets, 2015
  • Table 10.5: Incidence of Community Acquired Urinary Tract Infections in National Markets, 2015
  • Table 10.6: Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2015
  • Table 10.7: Incidence of Upper Respiratory Tract Infections in National Markets, 2015
  • Table 10.8: Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2013
  • Table 10.9: Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2013
  • Table 10.10: US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.11: EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.12: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.13: French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.14: German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.15: UK Early Stage Antibacterial Drug Developers, 2015
  • Table 10.16: UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.17: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.18: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.19: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.20: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.21: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.22: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.23: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 10.24: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
  • Table 11.1: Small Molecule Antibacterial Drug in Phase III Development, 2016
  • Table 11.2: Small Molecule Antibacterial Drug in Phase II Development, 2016
  • Table 11.3: Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical Development, 2016
  • Table 11.4: Biological Antibacterial Therapeutics in Clinical Development, 2016
  • Table 12.1: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2016-2026
  • Table 12.2: Bacterial Related Funding for BARDA, 2011-2014
  • Table 14.1: World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2014, 2015, 2020 and 2026

List of Figures

  • Figure 2.1: Leading Causes of Infectious Disease Deaths Worldwide, 2010
  • Figure 2.2: Key Events in the History of Antibacterial Drug Development
  • Figure 3.1: Historic Global Market Size ($bn), 2010-2015
  • Figure 3.2: Global Antibacterial Drug Market by Sector: Market Share (%), 2015
  • Figure 3.3: Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2016-2026
  • Figure 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2020
  • Figure 3.5: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2026
  • Figure 3.6: Ten Leading Branded Antibacterial Manufacturers: Market Share (%), 2014
  • Figure 4.1: Cephalosporin Market by Product: Market Share (%), 2015
  • Figure 4.2: Cephalosporin Market by Product: Market Share (%), 2020
  • Figure 4.3: Cephalosporin Market by Product: Market Share (%), 2026
  • Figure 4.4: Cephalosporin Market Forecast: Revenue ($bn), 2016-2026
  • Figure 4.5: Cephalosporin Market: Drivers and Restraints, 2016-2026
  • Figure 4.6: Rocephin Forecast: Revenue ($bn), 2016-2026
  • Figure 4.7: Sulperazon Forecast: Revenue ($bn), 2016-2026
  • Figure 4.8: Zinnat/Ceftin Forecast: Revenue ($bn), 2016-2026
  • Figure 4.9: Meiact Forecast: Revenue ($bn), 2016-2026
  • Figure 4.10: Flomox Forecast: Revenue ($bn), 2016-2026
  • Figure 4.11: Zinforo/Teflaro Forecast: Revenue ($bn), 2016-2026
  • Figure 4.12: Zeftera Forecast: Revenue ($bn), 2016-2026
  • Figure 4.13: Ceftolozane-Tazobactam Forecast: Revenue ($bn), 2016-2026
  • Figure 4.14: Ceftazidime-Avibactam Forecast: Revenue ($bn), 2016-2026
  • Figure 5.1: Penicillin Market by Product: Market Share (%), 2015
  • Figure 5.2: Penicillin Market by Product: Market Share (%), 2020
  • Figure 5.3: Penicillin Market by Product: Market Share (%), 2026
  • Figure 5.4: Penicillin Market Forecast: Revenue ($bn), 2016-2026
  • Figure 5.5: Augmentin Forecast: Revenue ($bn), 2016-2026
  • Figure 5.6: Zosyn/Tazocin Forecast: Revenue ($bn), 2016-2026
  • Figure 5.7: Unasyn Forecast: Revenue ($bn), 2016-2026
  • Figure 5.8: Amoxil Forecast: Revenue ($bn), 2016-2026
  • Figure 5.9: Generic Amoxicillin Forecast: Revenue ($bn), 2016-2026
  • Figure 5.10: Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2016-2026
  • Figure 6.1: Fluoroquinolone Market by Product: Market Share (%), 2015
  • Figure 6.2: Fluoroquinolone Market by Product: Market Share (%), 2020
  • Figure 6.3: Fluoroquinolone Market by Product: Market Share (%), 2026
  • Figure 6.4: Fluoroquinolone Market Forecast: Revenue ($bn), 2016-2026
  • Figure 6.5: Avelox Forecast: Revenue ($bn), 2016-2026
  • Figure 6.6: Cravit and Levaquin Forecast: Revenue ($bn), 2016-2026
  • Figure 6.7: Vigamox Forecast: Revenue ($bn), 2016-2026
  • Figure 6.8: Ciprodex Forecast: Revenue ($bn), 2016-2026
  • Figure 6.9: Cipro/Ciprobay Forecast: Revenue ($bn), 2016-2026
  • Figure 6.10: Geninax Forecast: Revenue ($bn), 2016-2026
  • Figure 6.11: Delafloxacin Forecast: Revenue ($bn), 2016-2026
  • Figure 7.1: Macrolide Market by Product: Market Share (%), 2015
  • Figure 7.2: Macrolide Market by Product: Market Share (%), 2020
  • Figure 7.3: Macrolide Market by Product: Market Share (%), 2026
  • Figure 7.4: Macrolide Market Forecast: Revenue ($bn), 2016-2026
  • Figure 7.5: Biaxin/Clarith Forecast: Revenue ($bn), 2016-2026
  • Figure 7.6: Zithromax Forecast: Revenue ($bn), 2016-2026
  • Figure 7.7: Dalacin Forecast: Revenue ($bn), 2016-2026
  • Figure 7.8: Dificid Forecast: Revenue ($bn), 2016-2026
  • Figure 7.9: Solithromycin Forecast: Revenue ($bn), 2016-2026
  • Figure 8.1: Carbapenem Market by Product: Market Share (%), 2015
  • Figure 8.2: Carbapenem Market by Product: Market Share (%), 2020
  • Figure 8.3: Carbapenem Market by Product: Market Share (%), 2026
  • Figure 8.4: Carbapenem Market Forecast: Revenue ($bn), 2016-2026
  • Figure 8.5: Merrem Forecast: Revenue ($bn), 2016-2026
  • Figure 8.6: Primaxin Forecast: Revenue ($bn), 2016-2026
  • Figure 8.7: Invanz Forecast: Revenue ($bn), 2016-2026
  • Figure 8.8: Doribax Forecast: Revenue ($bn), 2016-2026
  • Figure 9.1: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2015
  • Figure 9.2: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2020
  • Figure 9.3: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2026
  • Figure 9.4: Other Agents Market Forecast by Product: Revenue ($bn), 2016-2026
  • Figure 9.5: Zyvox Forecast: Revenue ($bn), 2016-2026
  • Figure 9.6: Cubicin Forecast: Revenue ($bn), 2016-2026
  • Figure 9.7: Tygacil Forecast: Revenue ($bn), 2016-2026
  • Figure 9.8: TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2016-2026
  • Figure 9.9: Solodyn Forecast: Revenue ($bn), 2016-2026
  • Figure 9.10: Vibativ Forecast: Revenue ($bn), 2016-2026
  • Figure 9.11: Sirturo Forecast: Revenue ($bn), 2016-2026
  • Figure 9.12: Tedizolid Forecast: Revenue ($bn), 2016-2026
  • Figure 9.13: Oritavancin Forecast: Revenue ($bn), 2016-2026
  • Figure 9.14: Dalbavancin Forecast: Revenue ($bn), 2016-2026
  • Figure 9.15: Surotomycin Forecast: Revenue ($bn), 2016-2026
  • Figure 9.16: Nemonoxacin Forecast: Revenue ($bn), 2016-2026
  • Figure 10.1: Antibacterial Drug Sales by National and Regional Markets: Market Share (%), 2015
  • Figure 10.2: Antibacterial Drug Market Forecasts: National and Regional Market Sizes ($bn), 2015-2026
  • Figure 10.3: Absolute Annual Antibacterial Drug Consumption by Nation, 2015
  • Figure 10.4: Per Capita Antibacterial Drug Consumption by Nation, 2015
  • Figure 10.5: US Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.6: EU Antibacterial Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2016-2026
  • Figure 10.7: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.8: French Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.9: German Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.10: UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.11: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.12: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.13: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.14: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), 2016-2026
  • Figure 10.15: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.16: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.17: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 10.18: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
  • Figure 12.1: Strengths and Weaknesses of the Antibacterial Drug Market, 2016-2026
  • Figure 12.2: Opportunities and Threats for the Antibacterial Drug Market, 2016-2026
  • Figure 12.3: Strategies and Technologies to Prevent Hospital Acquired Infections, 2016

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Achaogen
  • Actavis
  • Actelion
  • Affinium Pharmaceutical
  • AiCuris GmbH & Co. KG
  • Alcon
  • Alkem Laboratories
  • Allergan
  • Allied Pharma
  • ANVISA
  • Apotex
  • APP Pharmaceuticals
  • Aptalis Pharma
  • Aquapharm Biodiscovery
  • Aradigm
  • Aridis Pharmaceuticals
  • Ascend Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Pharmaceuticals
  • Basilea Pharmaceuticals
  • Bayer Laboratories
  • Biomax Biotechnics
  • Bristol-Myers Squibb
  • Cadila Healthcare
  • Calixa Therapeutics
  • Cardeas Pharma
  • Cellceutix
  • Cempra Pharmaceuticals
  • Cipla
  • Claris Lifesciences
  • Cornerstone Biopharma
  • Cornerstone Therapeutics
  • Corona Remedies
  • Critical Therapeutics
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Discuva
  • Dr. Reddy's Laboratories
  • Duke University
  • Durata Therapeutics
  • Eli Lilly
  • European Medicines Agency (EMA)
  • Emcure Pharmaceuticals
  • Eros Pharma
  • Food and Drug Administration (FDA)
  • Forest Laboratories
  • Furiex Pharmaceuticals
  • Gate Pharma
  • Gilead Sciences
  • Glenmark
  • GlycoVaxyn
  • GlaxoSmithKline (GSK)
  • Hetero
  • Hi Tech Pharma
  • Hikma Farmaceutica
  • Hospira
  • Insmed
  • Intercell
  • Itochu Chemical Frontier
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • KaloBios
  • Kenta Biotech
  • Kuhnil Pharm
  • Lupin
  • Macleod Pharmaceuticals
  • Medicis
  • MedImmune
  • Meiji
  • Melinta Therapeutics
  • Merck & Co.
  • Merlion Pharmaceuticals
  • Ministry of Health, Labour and Welfare (MHLW)
  • Michigan State University
  • Microlabs
  • MicuRx Pharmaceuticals
  • Mpex Pharmaceuticals
  • Mylan
  • Nabriva Therapeutics
  • Nalneva
  • Neiss Labs
  • Nektar Therapeutics
  • National Institute for Health and Clinical Excellence (NICE)
  • National Institutes of Health (NIH)
  • Novacta Biosystems
  • Novartis
  • Novexel
  • Optimer Biotechnology
  • Orchid Chemicals
  • Orchid Healthcare
  • Ortho-McNeil
  • Paratek Pharmaceuticals
  • Peninsula Pharmaceuticals
  • Pfizer
  • Pharmacia
  • Phico Therapeutics
  • Piramal Healthcare
  • Plenus Pharmaceuticals
  • Pliva
  • Polyphor
  • Procarta Biosystems
  • Procter & Gamble Pharmaceuticals
  • Ranbaxy
  • Redx Pharma
  • Roche
  • Roxane
  • R-Pharma
  • Sagent Pharmaceuticals
  • Sandoz
  • Sanofi
  • Savara Pharmaceuticals
  • Sawai Pharmaceutical
  • Schering Plough
  • Seika Pharma
  • Sequella
  • Shanghai MengKe Pharmaceuticals
  • Shionogi
  • Shire
  • Sidmak Labs
  • Solitaire Pharmacia
  • Specialised Therapeutics Australia
  • Sunovion Pharma
  • TaiGen Biotechnology
  • Taisho Toyama
  • Takeda
  • TAP Holdings
  • Targanta Therapeutics
  • Tetraphase Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theravance
  • Torrent Pharmaceuticals
  • Trius Therapeutics
  • TTY Biopharma
  • Unichem Laboratories
  • University of Connecticut
  • Valeant Pharmaceuticals
  • Vansen Pharma
  • ViroPharma
  • Warner Chilcott
  • Watson
  • World Health Organization (WHO)
  • Wockhardt
  • Zhejiang Medicine Company
  • Zuellig Pharma
  • Zydus Pharmaceuticals
Back to Top